Navigation Links
Trovagene Expands Business Development Efforts Through a Partnership with Leomics Associates, Inc.
Date:2/27/2012

SAN DIEGO, Feb. 27, 2012 /PRNewswire/ -- Trovagene, Inc. (Pink Sheets: TROV.PK), a developer of trans-renal molecular diagnostics, today announced that it has hired Leomics Associates, Inc. to expand its business development activities and monetize the company's high value intellectual property estate.

"Trovagene owns a significant portfolio of molecular diagnostic intellectual property with relevance for a broad array of clinical applications. While the company will focus its internal R&D efforts on laboratory-developed tests in oncology, we are seeking development and commercialization partners for in-vitro diagnostic (IVD) opportunities, and for the development of tests in other clinical areas such as infectious disease, non-invasive prenatal diagnostics, transplant medicine, and others," stated Antonius Schuh, Ph.D.,Trovagene's Chief Executive Officer. "We are pleased to be working with Leomics Associates to execute on our business development strategy. The firm's principals have a proven track record in the industry and, amongst others, led the development of the molecular diagnostic testing business of Quest Diagnostics, the largest laboratory testing business in the United States." 

About Trovagene, Inc.

Headquartered in San Diego, California, Trovagene is developing its patented technology for the detection of transrenal DNA and RNA, short nucleic acid fragments, originating from normal and diseased cell death that cross the kidney barrier and can be detected in urine.

Trovagene has a dominant patent position as it relates to transrenal molecular testing. It has U.S. and European patent applications and issued patents that cover testing for HPV and other infectious diseases, cancer, transplantation, prenatal and genetic testing. In addition, it owns worldwide rights to nucleophosmin-1 (NPM1), an informative biomarker for acute myeloid leukemia (AML) and mutations in the SF3B1 gene, which have been shown to be associated with chemotherapy response in CLL (chronic lymphocytic leukemia) patients.

Trovagene has filed a Form 10 with the SEC. More complete current information about Trovagene is contained in the filing.

About Leomics Associates, Inc.

Leomics Associates, Inc. is a molecular diagnostics-focused consulting firm with ten years of experience, having contributed to some of the most successful molecular diagnostic projects in the industry. Leomics is led by Dr. Jorge Leon, a pioneer in the development and commercialization of molecular diagnostics, who, amongst others, helped establish the molecular diagnostic testing business at Quest Diagnostics and led its development and strategy through their critical growth years.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on Trovagene's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement.

Contacts

Trovagene, Inc.
Stephen Zaniboni
Chief Financial Officer
+1 (858) 496-7466
szaniboni@trovagene.com
http://www.trovagene.com

Venanzio Ciampa
+1 (212) 217 9065
venanzio@thepromofact.com


'/>"/>
SOURCE Trovagene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Bayer Expands Its Hemophilia Leadership Development Program
2. AMPAC Fine Chemicals Expands Into Controlled Substance Manufacturing
3. Sanovas Expands Headquarters and Opens Manufacturing Site
4. PAREXEL Expands Alliance Network to Support Early Phase Patient Studies, Establishes Collaboration With University Hospitals Bristol NHS Foundation Trust
5. CutisPharma Expands Product Line with New Oral Suspension Prescription Compounding Kits
6. Myoderm Expands International Capabilities
7. FDA Expands Use of Endovascular Graft to Treat Aortic Tears
8. Particle Sciences Expands Its DOSE™ Program With Additional Proprietary Modeling Capabilities
9. FDA Expands Use of Prevnar 13 Vaccine for People Ages 50 and Older
10. Inspiration Biopharmaceuticals Expands Leadership Team with Four New Hires
11. FDA Expands Use of HIV Drug Isentress to Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... DIEGO , Oct. 12, 2017 AVACEN ... recognized the company with their  2017 New Product Innovation Award ... based on extensive primary and secondary medical device market research ... Medical, through its first-to-market OTC, drug-free pain relief product, the ... unique approach to treating fibromyalgia widespread pain. ...
(Date:10/11/2017)... PARK, Calif. , Oct. 11, 2017  BioPharmX ... national scientific team that developed an innovative way to ... quantity of the delivery of new drugs. ... 2017 Fall Clinical Dermatology Conference will show how researchers ... General Hospital, Harvard Medical School used a suite of ...
(Date:10/11/2017)... , Oct. 11, 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") ... Surgical facility in Las Piedras, Puerto Rico ... and blades. ... the facility sustained minor structural damage, temporary loss of ... Repairs have been completed, manufacturing operations have resumed, and ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... ... be giving viewers the lowdown on sciatica in a new episode of "Success ... focuses on current events and innovation and investigates each subject in-depth with passion ...
(Date:10/13/2017)... ... , ... “The Journey: From the Mountains to the Mission Field”: the story ... the Philippines. “The Journey: From the Mountains to the Mission Field” is the creation ... has taught all ages and currently teaches a class of ladies at her church, ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare ... program management, will showcase a range of technology and learning solutions at the ... Convention and Expo to be held October 14–18, 2017 at the Mandalay Bay ...
(Date:10/12/2017)... LA (PRWEB) , ... October 12, 2017 , ... Planet ... in the U.S., announced today its plans to open a flagship location in Covington, ... occupy the former Rooms To Go store next to Office Depot in the Holiday ...
(Date:10/12/2017)... ... 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of ... innovative new design of the shoulder pad. The shoulder pad provides optimal support ... your pain while using cold therapy. By utilizing ice and water that is circulated ...
Breaking Medicine News(10 mins):